Skip Navigation

Link to  the National Institutes of Health  
The Science of Drug Abuse and Addiction from the National Institute on Drug Abuse Archives of the National Institute on Drug Abuse web site
Go to the Home page
   
Assessing the Impact of Childhood Interventions on Subsequent Drug Use Home
Assessing the Impact of Childhood Interventions
on Subsequent Drug Use
skip navigation About the Conference
Agenda
Commissioned Papers
Barbara J. Burns, Ph.D.
Scott N. Compton, Ph.D.
Helen L. Egger, M.D.
Elizabeth M.Z. Farmer, Ph.D.
E. Jane Costello
Tonya D. Armstrong
Alaattin Erkanli
Paul E. Greenbaum
Chi-Ming Kam
Linda M. Collins
Selected Bibliography
Program Contacts

Report on the Developmental Epidemiology of Comorbid Psychiatric and Substance Use Disorders

Costello, Armstrong & Erkanli

Links to other parts of this paper:


Tables

Table 2. Rates of substance abuse/dependence and psychiatric comorbidity in community-based samples

Study

N

Age

Time frame

Pop rate of
a (%)

Pop rate of
b (%)

Rate of a in
b (%)

Rate of a in not
b (%)

Rate of b in
a (%)

Rate of b in not
a (%)

OR

CI

a=substance abuse/dependence, b=depression, in females

1

142

19

12 mo

12.4

8.5

     

18.8

7.1

3.1

1.0, 6.3

4

363

14 to 16

lifetime

10.5

6.9

     

11.1

4.8

2.5

0.8, 4.2

5

1420

9 to 16

3 mo

6.3

  

34.7

1.1

     

47.7

32.9, 62.5

6

271

16 to 19

lifetime

7.8

10.3

17.9

6.6

23.8

9.2

3.1

1.1, 5.1

7

674

17

12 mo

20.3

              

n/a

  

8

961

15

6 mo

8.9

9.7

           

4.4

2.9, 5.9

12

190

14 to 17

6 mo

5.3

12.5

     

32

11.2

3.7

1.5, 5.9

13

810

15 to 19

lifetime

10

32.96

20.1

5.3

49.3

17.7

4.5

3.7, 5.3

14

1507

14 to 18

lifetime

9.8

22.7

22.8

  

52.7

  

4.6

3.5, 5.7

15

1507

14 to 18

lifetime

6.2

24.8

     

47.9

16.8

4.5

3.5, 5.5

16

1710

14 to 18

lifetime

8.3

20.3

19.9

5.4

     

4.4

3.6, 5.2

18

2326

16 to 17

1 mo

10.4

15.5

  

6.3

18.9

  

2.2

1.8, 2.6

20

454

18

12 mo

12.6

26.4

22.6

13.8

29

18.3

1.8

1.3, 2.3

a=substance abuse/dependence, b=depression, in males

1

142

19

12 mo

12.4

8.5

     

18.8

7.1

3.1

1.0, 6.3

4

411

14 to 16

lifetime

10.5

6.9

     

11.1

4.8

2.5

0.8, 4.2

5

1420

9 to 16

3 mo

5.7

  

29.9

1.5

     

28

20.2, 35.8

6

271

16 to 19

lifetime

12.4, 12.4

4.6

28.6, 42.9

11.6, 11.0

10.5, 15.8

3.7, 3.0

6.1

0.2, 12.0

7

578

17

12 mo

22.8

              

n/a

  

8

961

15

6 mo

6.5

3.4

           

4.4

2.9, 5.9

12

211

14 to 17

6 mo

7.1

12.5

     

32

11.2

3.7

1.5, 5.9

13

698

15 to 19

lifetime

11.75

16.33

20.1

5.3

49.3

17.7

4.5

3.7, 5.3

14

1507

14 to 18

lifetime

9.8

22.7

22.8

  

52.7

  

4.6

3.5, 5.7

15

1507

14 to 18

lifetime

6.2

24.8

     

47.9

16.8

4.5

3.5, 5.5

16

1710

14 to 18

lifetime

8.3

20.3

19.9

5.4

     

4.4

3.6, 5.2

18

2181

16 to 17

1 mo

11

12

  

7.2

22.7

  

3.4

2.8, 4.0

20

476

18

12 mo

60.7

13.9

22.6

13.8

29

18.3

1.8

1.3, 2.3

a=substance abuse/dependence, b=anxiety, in females

1

142

19

12 mo

12.4

8.1

     

33.3

  

10.4

3.5, 17.3

4

363

14 to 16

lifetime

10.5

4.4

     

7.4

3

3.2

1.0, 7.1

5

1420

9 to 16

3 mo

6.3

  

18.7

1.1

     

20

13.5. 26.5

6

271

16 to 19

lifetime

5.9, 7.8

              

n/a

  

7

674

17

12 mo

20.3

              

n/a

  

8

961

15

6 mo

8.9

18.6

           

2.4

1.7, 3.1

12

190

14 to 17

6 mo

5.3

16

     

20

15.7

1.5

0.5, 2.5

13

810

15 to 19

lifetime

10

12.35

15.3

7.6

16.2

8.1

2.2

1.4, 3.6

14

1507

14 to 18

lifetime

9.8

8.2

19.4

  

16.2

  

0.4

0.2, 0.6

15

1507

14 to 18

lifetime

6.2

8.2

     

27.1

9.2

3.7

2.8, 4.6

16

1710

14 to 18

lifetime

8.3

8.7

           

n/a

  

18

2326

16 to 17

1 mo

10.4

15.5

  

6.3

18.9

  

3

2.4, 3.6

20

454

18

12 mo

12.6

37.9

15.5

15.6

27.6

27.8

3.3

2.5, 4.1

a=substance abuse/dependence, b=anxiety, in males

1

142

19

12 mo

12.4

8.1

     

33.3

  

10.4

3.5, 17.3

4

411

14 to 16

lifetime

10.5

4.4

     

7.4

3

3.2

1.0, 7.1

5

1420

9 to 16

3 mo

5.7

  

4.8

1.5

     

3.3

n/a

6

271

16 to 19

lifetime

12.4, 12.4

              

n/a

  

7

578

17

12 mo

22.8

              

n/a

  

8

961

15

6 mo

6.5

6.9

           

2.4

1.7, 3.1

12

211

14 to 17

6 mo

7.1

16

     

20

15.7

1.5

0.5, 2.5

13

698

15 to 19

lifetime

11.75

5.44

15.3

7.6

16.2

8.1

2.2

1.6, 2.8

14

1507

14 to 18

lifetime

9.8

8.2

19.4

  

16.2

  

2.5

1.9, 3.1

15

1507

14 to 18

lifetime

6.2

8.2

     

6.5

6.4

1

0.6, 1.4

16

1710

14 to 18

lifetime

8.3

8.7

           

n/a

  

18

2181

16 to 17

1 mo

11

12

  

7.2

22.7

  

1.3

1.1, 1.5

20

476

18

12 mo

60.7

18.1

15.5

15.6

27.6

27.8

3.3

2.5, 4.1

a=substance abuse/dependence, b=ADHD, in females

1

142

19

12 mo

12.4

8.5

           

n/a

  

4

363

14 to 16

lifetime

10.5

5.2

     

12.3

1.8

5.4

0.2, 10.6

5

1420

9 to 16

3 mo

6.3

  

26.2

1.1

     

31.8

21.4, 42.2

6

271

16 to 19

lifetime

                 

n/a

  

7

674

17

12 mo

20.3

3.6

29.2

20

5.1

3.2

2.1

1.2, 3.0

8

961

15

6 mo

8.9

2.7

           

7

4.5, 9.5

12

190

14 to 17

6 mo

5.3

13.8

     

68

10.1

20.3

7.6, 33.0

13

810

15 to 19

lifetime

10

1.73

28.8

6.7

25.4

5.7

5.6

4.3, 6.9

14

1507

14 to 18

lifetime

9.8

6.2

35.1

  

22.3

  

5.9

4.5, 7.3

15

1507

14 to 18

lifetime

6.2

6.2

     

25.5

2.5

13.9

9.8, 18.0

16

1710

14 to 18

lifetime

8.3

              

n/a

  

18

2326

12 to 17

1 mo

10.4

              

n/a

  

20

454

18

12 mo

12.6

              

n/a

  

Note.

Study 1. Beitchman, Douglas, Wilson, Johnson, Young, Atkinson, Escobar, & Taback, 1999

Study 4. Chong, Chan, & Cheng, 1999

Study 5. Costello, Erkanli, Federman, & Angold, 1999

Study 6. Deykin, Levy, & Wells, 1987

Study 7. Disney, Elkins, McGue, & Iacono, 1999

Study 8. Fergusson, Horwood, & Lynskey, 1993

Study 12. Kandel, Johnson, Bird, Weissman, Goodman, Lahey, Regier, & Schwab-Stone, 1999

Study 13. Lewinsohn, Hops, Roberts, Seeley, & Andrews, 1995

Study 14. Lewinsohn, Rohde, & Seeley, 1995

Study 15. Rohde, Lewinsohn, & Seeley, 1996

Study 16. Rohde, Lewinsohn, & Seeley, 1991

Study 18. Substance Abuse and Mental Health Services Administration, 1999

Study 20. Feehan, McGee, Raja, & Williams, 1994

ADHD = attention-deficit/hyperactivity disorder; CD = conduct disorder; CI = confidence intervals; ODD = oppositional defiant disorder; OR = odds ratio

Back to Top



Archive Home | Accessibility | Privacy | FOIA (NIH) | Current NIDA Home Page
National Institutes of Health logo_Department of Health and Human Services Logo The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH) , a component of the U.S. Department of Health and Human Services. Questions? See our Contact Information. . The U.S. government's official web portal